Skip to main content
Signal8
Launch Terminal

Emergent BioSolutions Inc. (EBS)

Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.

Sector: Pharmaceutical Preparations

Industry: Drug Manufacturers - Specialty & Generic

Emergent BioSolutions Inc. logo

Emergent BioSolutions Inc.

NYSE:EBSHealthcare
-5.68%$6.81
AH$6.81+0.00%vs close
Mkt Cap$349.17M
Float50.3M
O/S51.27M
Vol
$ Vol
RVOL
Inst Own88.0%
SI19.3%
Earnings
Dilution
Emergent BioSolutions Inc. logoNYSE:EBS$6.81-5.68%
Phase Distribution
47 lead-sponsored trials·2 active·35 completed
Phase 118
Phase 1/21
Phase 28
Phase 2/31
Phase 34
Phase 44
Not applicable11
(17 more as collaborator)
Status Overview
Not yet recruiting5
Recruiting2
Completed35
Stopped5

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Enrolling by invitation

    BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients

    Blood sample collection

    Botulism

    Enrollment
    10
    Start
    Oct 2014
    Primary Completion
    Jul 2028est.
    Completion
    Jul 2028est.
    NCT02051062
  • Phase 4
    Not yet recruiting

    Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario

    Sample Collection

    Infections, Bacterial

    Enrollment
    100
    Start
    Jan 2027est.
    Primary Completion
    May 2035est.
    Completion
    Dec 2035est.
    NCT02177721
  • Phase 4
    Completed

    Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed

    AVA, Raxibacumab

    Infections, Bacterial

    Enrollment
    573
    Start
    Feb 2015
    Primary Completion
    Jan 2017
    Completion
    Jun 2017
    NCT02339155
  • Phase 4
    Completed

    VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV

    Vaccination with ACAM2000

    Smallpox Vaccine Adverse Reaction

    Enrollment
    3,032
    Start
    Sep 2015
    Primary Completion
    Jul 2021
    Completion
    Aug 2021
    NCT02443623
  • Phase 3
    Completed

    VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV

    ACAM2000

    Smallpox Vaccine Adverse Reaction

    Enrollment
    25
    Start
    Sep 2010
    Primary Completion
    Feb 2012
    Completion
    Feb 2012
    NCT01158157
  • Phase 3
    Terminated

    Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

    hepatitis B vaccine, hepatitis B vaccine

    Healthy Volunteers

    Enrollment
    141
    Start
    Sep 2009
    Primary Completion
    Mar 2011
    Completion
    Mar 2011
    NCT01311674
  • Phase 3
    Completed

    Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults

    BioThrax

    Anthrax

    Enrollment
    200
    Start
    Nov 2011
    Primary Completion
    May 2012
    Completion
    May 2012
    NCT01491607
  • Phase 3
    Completed

    VELOCITY: An Anthrax Vaccine Clinical Study

    AV7909, BioThrax

    Anthrax

    Enrollment
    3,689
    Start
    Mar 2019
    Primary Completion
    Aug 2020
    Completion
    Aug 2020
    NCT03877926
  • Phase 2/3
    Completed

    HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma

    HuMax-CD4

    T Cell Lymphoma

    Enrollment
    21
    Start
    Aug 2005
    Primary Completion
    Jan 2006
    Completion
    Dec 2008
    NCT00877656
  • Phase 2
    Completed

    Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

    ACAM2000 Smallpox Vaccine, Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®

    Smallpox

    Enrollment
    357
    Start
    Jan 2003
    Primary Completion
    Apr 2003
    Completion
    Oct 2003
    NCT00053482
  • Phase 2
    Completed

    Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination

    Vaccinia virus: ACAM2000 smallpox vaccine, vaccinia virus (calf lymph): Dryvax

    Smallpox

    Enrollment
    353
    Start
    Jan 2003
    Primary Completion
    Jun 2003
    Completion
    Nov 2003
    NCT00053495
  • Phase 2
    Completed

    Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

    Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (Cohort 2)

    Typhoid

    Enrollment
    187
    Start
    May 2008
    Primary Completion
    Dec 2008
    Completion
    Dec 2008
    NCT00679172
  • Phase 2
    Terminated

    CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma

    CHOP + CD4, CHOP

    T-cell Lymphoma

    Enrollment
    5
    Start
    May 2007
    Primary Completion
    Oct 2008
    Completion
    Dec 2008
    NCT00893516
  • Phase 2
    Completed

    Ciprofloxacin BioThrax Co-Administration Study

    BioThrax, Ciprofloxacin

    Anthrax

    Enrollment
    154
    Start
    Dec 2012
    Primary Completion
    Aug 2013
    Completion
    Aug 2013
    NCT01753115
  • Phase 2
    Completed

    A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels

    AV7909, BioThrax

    Anthrax

    Enrollment
    168
    Start
    Jan 2013
    Primary Completion
    Feb 2014
    Completion
    Dec 2014
    NCT01770743
  • Phase 2
    Completed

    Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A

    FLU-IGIV

    Influenza A H3N2, Influenza A H1N1

    Enrollment
    65
    Start
    Nov 2017
    Primary Completion
    Jun 2019
    Completion
    Jun 2019
    NCT03315104
  • Phase 2
    Completed

    Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study

    Ciprofloxacin 500Mg Tablet, Doxycycline 100Mg Tablet

    Anthrax

    Enrollment
    210
    Start
    Aug 2019
    Primary Completion
    Mar 2020
    Completion
    Mar 2020
    NCT04067011
  • Phase 1/2
    Completed

    Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

    AIGIV 3.5 mg/kg, Gamunex 90 mg/kg

    Anthrax

    Enrollment
    129
    Start
    Feb 2009
    Primary Completion
    Oct 2010
    Completion
    Oct 2010
    NCT00845650
  • Phase 1
    Completed

    Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses

    Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)

    Healthy

    Enrollment
    40
    Start
    Jul 2006
    Primary Completion
    Dec 2006
    Completion
    Apr 2010
    NCT00360737
  • Phase 1
    Completed

    Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum

    NP-015

    Symptoms of Inhalational Anthrax

    Enrollment
    92
    Start
    Jul 2007
    Primary Completion
    Aug 2008
    Completion
    Sep 2008
    NCT00448253
  • Phase 1
    Completed

    Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle

    Botulism Antitoxin Bivalent (Equine) Types A and B, Botulism Antitoxin Heptavalent (Equine) Types A-G

    Healthy Volunteers

    Enrollment
    36
    Start
    Feb 2008
    Primary Completion
    Oct 2009
    Completion
    Oct 2009
    NCT00636519
  • Phase 1
    Completed

    Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

    Ad4-H5-Vtn, Sanofi Pasteur Influenza Virus Vaccine, H5N1

    Bird Flu, Influenza

    Enrollment
    166
    Start
    Oct 2009
    Primary Completion
    Sep 2011
    Completion
    Sep 2011
    NCT01006798
  • Phase 1
    Completed

    Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)

    AVP-21D9, Placebo

    Anthrax

    Enrollment
    50
    Start
    Aug 2010
    Primary Completion
    Jun 2011
    Completion
    Jun 2011
    NCT01202695
  • Phase 1
    Completed

    Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults

    BioThrax, AV7909 Formulation 1

    Bacillus Anthracis (Anthrax) Infection

    Enrollment
    105
    Start
    Dec 2010
    Primary Completion
    May 2012
    Completion
    Jun 2012
    NCT01263691
  • Phase 1
    Completed

    A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines

    AVA, Ad4-PA-1

    Anthrax Infection

    Enrollment
    120
    Start
    Nov 2013
    Primary Completion
    Oct 2014
    Completion
    Sep 2015
    NCT01979406

1-25 of 47

Search ClinicalTrials.gov for “Emergent BioSolutions”